Sort
82,697 grants matching “vaccine development”
Discovery of Novel Broad-Spectrum Coronavirus Mpro Inhibitors
$785,196Julien Papillon · University Of Texas Med Br Galveston · U19 · FY2023 · AI
Mechanisms of myocarditis and progressive cardiac fibrosis in chronic Trypanosoma cruzi infection.
$785,194Kathryn Marie Jones · Baylor College Of Medicine · R01 · FY2023 · AI
Entry and replication of positive-sense, RNA viruses
$785,051Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Preclinical Assessment of a Multi-Head Electroporation Device for Delivery of Bio
$785,031Kathleen A Cashman · Geneva Foundation · R01 · FY2017 · AI
Defining the role of T cell help in germinal centers by intercellular enzymatic labeling
$785,027Gabriel D Victora · Rockefeller University · R01 · FY2022 · AI
Understanding and optimizing antibody-based interventions against neonatal HSV infection
$785,011Margaret E Ackerman · Dartmouth College · R01 · FY2024 · AI
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2021 · DA
Host-Directed Strategies to Create Synergistic Antibacterial Therapies
$785,000Jeffery S Cox · University Of California Berkeley · DP1 · FY2016 · AI
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2019 · DA
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2018 · DA
Host-Directed Strategies to Create Synergistic Antibacterial Therapies
$785,000Jeffery S Cox · University Of California Berkeley · DP1 · FY2018 · AI
Host-Directed Strategies to Create Synergistic Antibacterial Therapies
$785,000Jeffery S Cox · University Of California Berkeley · DP1 · FY2017 · AI
Host-Directed Strategies to Create Synergistic Antibacterial Therapies
$785,000Jeffery S Cox · University Of California Berkeley · DP1 · FY2019 · AI
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2020 · DA
Targeting natural killer cells to HIV in intravenous drug users
$785,000Catherine A Blish · Stanford University · DP1 · FY2022 · DA
A Peptide Nanoparticle Nicotine Vaccine
$785,000Peter Burkhard · University Of Connecticut Storrs · DP1 · FY2011 · DA
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines
$784,979David R. Milich · Vaccine Research Institute Of San Diego · R01 · FY2010 · AI
Cytotoxic T Cell Mediated Immunity to Chlamydia
$784,976Michael N Starnbach · Harvard Medical School · R01 · FY2018 · AI
Cytotoxic T Cell Mediated Immunity to Chlamydia
$784,976Michael N Starnbach · Harvard Medical School · R01 · FY2020 · AI
Cytotoxic T Cell Mediated Immunity to Chlamydia
$784,976Michael N Starnbach · Harvard Medical School · R01 · FY2017 · AI
Cytotoxic T Cell Mediated Immunity to Chlamydia
$784,976Michael N Starnbach · Harvard Medical School · R01 · FY2019 · AI
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection
$784,941Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2021 · AI
Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection
$784,938Charles A. Scanga · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop
$784,933Susan B Zolla-Pazner · New York University School Of Medicine · P01 · FY2016 · AI
Quantifying the Breadth and Duration of Immunity Induced by Meningococcal B Vaccines
$784,845Nicole Elaine Basta · University Of Minnesota · R01 · FY2018 · AI